Published in JAMA on July 11, 2001
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol (2004) 3.13
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med (2008) 2.94
Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol (2003) 2.31
Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol (2006) 1.82
Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol (2005) 1.34
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog (2007) 1.23
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol (2006) 1.05
HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS (2014) 0.93
HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels. World J AIDS (2013) 0.77
Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med (2001) 3.69
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2001) 2.84
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med (2001) 2.13
Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet (1996) 2.03
Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS (2000) 1.18
Antiretroviral therapy for HIV infection: promises and problems. JAMA (1998) 1.16
Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis (2000) 1.14
Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. AIDS (2001) 1.09
Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS (2001) 1.06
Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol (2011) 1.04
Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am J Transplant (2014) 0.90
Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. Neurology (2008) 0.88
Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses (2001) 0.88
Variations in the heme oxygenase-1 microsatellite polymorphism are associated with plasma CD14 and viral load in HIV-infected African-Americans. Genes Immun (2011) 0.86
Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes. AIDS (2001) 0.82
Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints. J Virol (2014) 0.78
Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients. Clin Exp Immunol (2012) 0.75
Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med (2015) 0.75
Should we argue with success? AIDS Clin Care (1998) 0.75